Worth Venture Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Worth Venture Partners’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,969	Closed	-$22K	–	100
2018 Q4	$22K	Sell	1,969 -1	-0.1%	-$17	0.02%	82
2018 Q3	$44K	Sell	1,970 -9,849	-83%	-$200K	0.03%	139
2018 Q2	$227K	Sell	11,819 -895	-7%	-$11.3K	0.19%	62
2018 Q1	$140K	Buy	+12,714	New	+$216K	0.12%	82

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Worth Venture Partners's ATNM Position: Q1 2019 in Review

Worth Venture Partners sold out of Actinium Pharmaceuticals (ATNM) in Q1 2019, closing a stake of 1,969 shares — an estimated $22K sold.

Worth Venture Partners first reported a position in ATNM in Q1 2018 and held it in 4 quarters. The position peaked at $227K in Q2 2018. 43 funds tracked by Wall St. Rank hold ATNM as of Q1 2019.

Worth Venture Partners reported no remaining Actinium Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Worth Venture Partners sold 1,969 Actinium Pharmaceuticals shares in Q1 2019, an estimated $22K.
Worth Venture Partners first reported a position in Actinium Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Worth Venture Partners's Actinium Pharmaceuticals position peaked at $227K in Q2 2018.
43 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2019.

Based on Worth Venture Partners's 13F filing for Q1 2019, filed 15 May 2019.